Science

"Google’s climate scientists are not happy with the company’s political support for climate science denying Senator James Inhofe (R-OK)."

"WASHINGTON -- Fish and Wildlife Service Director Dan Ashe failed for more than a year to discipline two supervisors who retaliated against whistle-blowers at an Oklahoma field office, the Interior Department's inspector general says in a harshly worded letter that accuses Ashe of damaging the agency's credibility and integrity."

Some chemicals can cause cancer. But the chemical industry, unable to get the results it wants from toxicologists at the National Institute for Environmental Health Sciences, is now trying to get them by using lawyers, lobbyists, and legislators.

"Images of a scientific observation buoy floating in what appeared to be an Arctic lake near the North Pole lit up the online world in the past week, sparking questions about whether this was a sign of global warming."

"Republican strategists have laid out an aggressive game plan for seizing the high ground on energy during the August recess: talk about gas prices and jobs, jobs, jobs."

"An EPA staff report suggests methane from hydraulic fracturing, or fracking, contaminated wells near Dimock, Pa., but the agency says the water's safe to drink."

"Two decisions handed down July 19 in DC Superior Court affirmed climate scientist Michael Mann’s right to proceed in his defamation lawsuit against the Competitive Enterprise Institute and the National Review Online for their statements accusing him of data manipulation and fraud. The Court is not buying the Defendants arguments in their Motion to Dismiss that their statements are protected speech under the First Amendment, mere 'opinion,' 'rhetorical hyperbole,' or 'fair comment.'"

"Last week, former Reuters reporter David Fogarty published a scathing letter online accusing his former employer of abandoning coverage of climate change."

A Texas trial is pitting the giant Eastman Chemical against two small labs who said
Eastman's "BPA-free" plastic Tritan still had estrogen-like activity. The trial raises key issues about whether the objectivity of science is skewed by who pays for it -- and whether financial interests should be disclosed.